Numéro |
Therapie
Volume 69, Numéro 4, Juillet-Août 2014
XXIXes Rencontres nationales de Pharmacologie et Recherche clinique, pour l’Innovation et l’Évaluation des Technologies de Santé Tables rondes GIENS – 6 au 8 octobre 2013
|
|
---|---|---|
Page(s) | 331 - 338 | |
Section | Médico-économie / Medico-Economy | |
DOI | https://doi.org/10.2515/therapie/2014048 | |
Publié en ligne | 12 août 2014 |
Medico-economic Evaluation of Healthcare Products. Methodology for Defining a Significant Impact on French Health Insurance Costs and Selection of Benchmarks for Interpreting Results
1
Délégation à la recherche clinique et à l’innovation,
CHRU, Lille,
France
2
Laboratoire Lilly, Neuilly sur Seine,
France
3
Comité économique des produits de santé,
Paris,
France
4
Direction de la sécurité sociale, Paris, France
5
AMGEN, Neuilly
sur Seine, France
6
Laboratoire Janssen Cilag, Issy les Moulineaux,
France
7
Medtronic, Boulogne Billancourt, France
8
CEMKA-EVAL, Bourg
la Reine, France
9
Boston Scientific, Saint Quentin en Yvelines,
France
10
LEEM, Paris, France
11
ANAP, Paris, France
12
Direction générale de la santé, Paris, France
13
GlaxoSmithKline, Marly le Roy, France
14
CNAMTS, Paris, France
15
MSD-Chibret, Courbevoie, France
16
Association française des hémophiles, Paris, France
17
Laboratoire Roche, Boulogne Billancourt,
France
18
Institut Pasteur, Paris, France
Correspondence and offprints:
Benoit Dervaux, Délégation à la recherche clinique et à l’innovation,
CHRU Lille, 1 avenue Oscar Lambret, 59037 Lille Cedex, France. E-mail:
benoit.dervaux@chru-lille.fr
Received:
9
June
2014
Accepted:
11
June
2014
Decree No. 2012-1116 of 2 October 2012 on medico-economic assignments of the French National Authority for Health (Haute autorité de santé, HAS) significantly alters the conditions for accessing the health products market in France. This paper presents a theoretical framework for interpreting the results of the economic evaluation of health technologies and summarises the facts available in France for developing benchmarks that will be used to interpret incremental cost-effectiveness ratios. This literature review shows that it is difficult to determine a threshold value but it is also difficult to interpret then incremental cost effectiveness ratio (ICER) results without a threshold value. In this context, round table participants favour a pragmatic approach based on “benchmarks” as opposed to a threshold value, based on an interpretative and normative perspective, i.e. benchmarks that can change over time based on feedback.
Key words: medico-economic evaluation / cost-effectiveness ratio / benchmarks / acceptability threshold
© 2014 Société Française de Pharmacologie et de Thérapeutique